Citi initiated coverage of MiniMed (MMED) with a Buy rating and $23 price target The firm says the company has a full pipeline of diabetes products and offers double-digit revenue growth with expanding EBITDA. It views the stock’s valuation discount to peers as too wide.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMED: